About us

CSL Behring Recombinant Facility (RCF) AG in Lengnau

The new production site in Lengnau is part of the CSL Group of Companies. When fully operational in 2020, Lengnau will manufacture the company's recombinant products with more than 300.  

 

CSL Behring AG in Bern

At the site in Bern, CSL Behring AG has over 1,400 employees who develop, manufacture and distribute high-quality biotherapies made from human plasma, which meet the highest safety standards. The products of CSL Behring AG include immunoglobulines for the treatment of immune deficiencies and disturbances of the immune function, an intravenous immunoglobulin for preventing cytomegalovirus disease associated with solid organ transplantation as well as an anti-D immunoglobulin to prevent hemolytic disease in the newborn resulting from Rh factor incompatibilities, and albumin. The latter is used in emergency medicine and critical care settings. The products of CSL Behring AG are distributed worldwide. Major markets are the U.S., Europe, Japan, Latin America and the Middle East.

The production facilities of CSL Behring AG are licensed by the Swiss health authorities (Swissmedic), Australia (TGA), North America (FDA), Europe (EMA) and other regulators. Each year, therapeutically important proteins are isolated from more than ten million litres of human plasma and manufactured into therapies.

In research and development, CSL Behring AG in Bern collaborates closely with the globally integrated R&D facilities of the CSL Group in Australia, the U.S., Germany and Japan. Furthermore, the company cooperates with industrial partners, research institutes, and universities locally and globally.

Read more about CSL Behring AG (website in German).

CSL global network

 

 CSL Behring AG in Bern

CSL Behring

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies to treat people with life-threatening medical conditions. Our therapeutics are used for treatments such as coagulation (bleeding) disorders, primary immune deficiencies, hereditary angiooedema, genetic emphysema (inherited respiratory disease) and neurological disorders. Our products are also used in cardiac surgery and organ transplantation, to treat severe burns and to prevent hemolytic disease in the newborn.

CSL Behring, as a subsidiary of CSL Limited that was founded in 1916, has a long tradition of life-saving therapies. It traces its beginnings to the 1904 founding of Behringwerke in Marburg, Germany, a company established by Emil von Behring, and the Zentrallaboratorium Blutspendedienst (ZLB), which was established in Bern as a department of the Swiss Red Cross in 1949. In 2000, CSL acquired ZLB and renamed it to ZLB Bioplasma, headquartered in Bern, Switzerland. Following CSL's acquisition of Aventis Behring and its combination with ZLB Bioplasma in 2004, today's CSL Behring was created. With production sites in Bern (Switzerland), Marburg (Germany), Broadmeadows (Australia) and Kankakee (U.S.), the company has over 14,000 employees worldwide. CSL Behring's headquarters are in King of Prussia, Pennsylvania, U.S.

Through CSL Plasma, CSL Behring operates one of the world's largest plasma collection networks with over 150 plasma collection centres in the U.S. and Europe.

Read more about CSL Behring.

 

CSL Limited

CSL Limited is a leading global biotherapeutics company with a dynamic portfolio of life-saving innovations, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL -  including our two businesses CSL Behring and Seqirus - operates in over 30 countries and delivers medicines with its nearly 20,000 employees to more than 60 countries. The company has it headquarters in Melbourne, Australia. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. 

Read more about CSL Limited.

© 2017 CSL Behring